GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Balance Sheet Cash And Cash Equivalents

Shire (SHPG) Balance Sheet Cash And Cash Equivalents


View and export this data going back to 1998. Start your Free Trial

What is Shire Balance Sheet Cash And Cash Equivalents?

Please go to this page to see Cash And Cash Equivalents for non-financial companies.


Shire (SHPG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Balance Sheet Cash And Cash Equivalents
Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085